|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
US8143283B1
(en)
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
|
US6518281B2
(en)
|
1995-08-29 |
2003-02-11 |
Celgene Corporation |
Immunotherapeutic agents
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
EP1586322B1
(en)
*
|
1996-11-05 |
2008-08-20 |
The Children's Medical Center Corporation |
Compositions comprising thalodimide and dexamethasone for the treatment of cancer& x9;
|
|
NZ509376A
(en)
*
|
1998-07-09 |
2003-10-31 |
Francis A Nardella |
Indole or carbazole derivatives for the treatment of chronic lyphocytic leukemia
|
|
US6235782B1
(en)
*
|
1998-11-12 |
2001-05-22 |
Rifat Pamukcu |
Method for treating a patient with neoplasia by treatment with a platinum coordination complex
|
|
EP1131076A4
(en)
*
|
1998-11-12 |
2004-04-14 |
Osi Pharm Inc |
TREATMENT OF NEOPLASIA IN A PATIENT BY ADMINISTRATION OF ANTHRACYCLINE
|
|
US6235776B1
(en)
*
|
1998-11-12 |
2001-05-22 |
Cell Pathways, Inc. |
Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
|
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
|
TR200102688T2
(tr)
|
1999-03-18 |
2002-01-21 |
Celgene Corporation |
İkameli 1-okso ve 1,3-dioksoizoindolinler ve enflamatuar sitokin seviyelerinin azaltılması için farmasötik bileşimlerde kullanımları.
|
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
MXPA01011344A
(es)
*
|
1999-05-07 |
2004-06-03 |
Univ Johns Hopkins Med |
El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.
|
|
MY164077A
(en)
*
|
1999-05-13 |
2017-11-30 |
Pharma Mar Sa |
Compositions and uses of et743 for treating cancer
|
|
WO2000072836A2
(en)
*
|
1999-05-27 |
2000-12-07 |
The Rockefeller University |
Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
|
|
US7105560B1
(en)
*
|
1999-07-23 |
2006-09-12 |
The Regents Of The University Of California |
Use of etodolac in the treatment of multiple myeloma
|
|
US7105172B1
(en)
*
|
1999-11-18 |
2006-09-12 |
Bolla John D |
Treatment of rosacea
|
|
EP1279406A4
(en)
*
|
2000-04-03 |
2007-10-24 |
Santen Pharmaceutical Co Ltd |
TRANSPORTERS AND DRUG DISPENSING SYSTEMS USING THESE
|
|
WO2001085175A2
(en)
*
|
2000-05-11 |
2001-11-15 |
Oklahoma Medical Research Foundation |
Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with ns398 or pdtc
|
|
AU2001280804A1
(en)
*
|
2000-07-27 |
2002-02-13 |
Eileen R. Blasi |
Aldosterone blocker therapy to prevent or treat inflammation-related disorders
|
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
CA2430669C
(en)
*
|
2000-11-30 |
2011-06-14 |
The Children's Medical Center Corporation |
Synthesis of 3-amino-thalidomide and its enantiomers
|
|
EP1389203B8
(en)
|
2001-02-27 |
2010-03-10 |
The Governement of the United States of America, represented by The Secretary Department of Health and Human services |
Analogs of thalidomide as angiogenesis inhibitors
|
|
IL142037A0
(en)
|
2001-03-15 |
2002-03-10 |
Agis Ind 1983 Ltd |
Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
|
|
US6344479B1
(en)
*
|
2001-03-20 |
2002-02-05 |
Farmacon-Il, Llc |
Method of preventing retinopathy of prematurity in a neonate
|
|
EP1380302B1
(en)
*
|
2001-03-28 |
2008-08-20 |
Santen Pharmaceutical Co., Ltd. |
Remedies for retina and choroid diseases containing steroids as the active ingredient
|
|
WO2003014315A2
(en)
*
|
2001-08-06 |
2003-02-20 |
The Children's Medical Center Corporation |
Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
|
|
US20040254197A1
(en)
*
|
2001-09-28 |
2004-12-16 |
Santen Pharmaceutical Co., Ltd. |
Injections for eye tissues containing drug bonded to polyethlene glycol
|
|
CN1981761B
(zh)
*
|
2002-05-17 |
2011-10-12 |
细胞基因公司 |
使用免疫调节性化合物用于制备治疗和控制癌症和其它疾病药物中的应用及组合物
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
|
US8263637B2
(en)
*
|
2002-05-17 |
2012-09-11 |
Celgene Corporation |
Methods for treatment of multiple myeloma using cyclopropane carboxylic acid {2-[(is)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 h-isoindol-4-yl}-amide
|
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US7842691B2
(en)
*
|
2002-10-15 |
2010-11-30 |
Celgene Corporation |
Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
|
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
|
EP1562597A4
(en)
*
|
2002-10-31 |
2008-05-14 |
Celgene Corp |
COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MACULAR DEGENERATION AND METHODS OF USE THEREOF
|
|
US20040091455A1
(en)
*
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
|
EP1567154A4
(en)
|
2002-11-06 |
2006-05-31 |
Celgene Corp |
METHODS AND COMPOSITIONS USING CYTOKINE SELECTIVE INHIBITION DRUGS FOR TREATING AND CONTROLLING CANCERS AND OTHER DISEASES
|
|
US7230012B2
(en)
*
|
2002-11-14 |
2007-06-12 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
|
US9006267B2
(en)
*
|
2002-11-14 |
2015-04-14 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
CA2808646C
(en)
|
2003-09-17 |
2016-08-23 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Thalidomide analogs as tnf-alpha modulators
|
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
|
US20080027113A1
(en)
*
|
2003-09-23 |
2008-01-31 |
Zeldis Jerome B |
Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
|
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
|
KR20060124607A
(ko)
*
|
2003-11-06 |
2006-12-05 |
셀진 코포레이션 |
암 및 그 밖의 질환의 치료 및 관리를 위하여탈리도마이드를 사용하는 방법 및 조성물
|
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
|
NZ550026A
(en)
*
|
2004-03-22 |
2009-10-30 |
Celgene Corp |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
|
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
|
WO2005110408A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
|
CA2563207A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
|
|
AU2005237490A1
(en)
*
|
2004-04-23 |
2005-11-10 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
|
|
KR101224368B1
(ko)
*
|
2004-06-04 |
2013-01-22 |
더 스크립스 리서치 인스티튜트 |
혈관신생 질환 치료용 조성물 및 방법
|
|
WO2006055672A2
(en)
*
|
2004-11-16 |
2006-05-26 |
Limerick Neurosciences, Inc. |
Methods and compositions for treating pain
|
|
US20070087977A1
(en)
*
|
2004-11-16 |
2007-04-19 |
Wendye Robbins |
Methods and compositions for treating pain
|
|
MX2007006063A
(es)
*
|
2004-11-23 |
2007-07-11 |
Celgene Corp |
Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central.
|
|
AU2006210787C1
(en)
*
|
2005-02-02 |
2013-01-17 |
Nexgenix Pharmaceuticals, L.L.C. |
Local treatment of neurofibromas
|
|
US7442690B2
(en)
*
|
2005-03-14 |
2008-10-28 |
P & L Enterprise Llc |
Topical treatment for psoriasis
|
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
|
CA2615975C
(en)
*
|
2005-07-22 |
2012-11-27 |
The Procter & Gamble Company |
Compositions for reducing the incidence of drug induced arrhythmia
|
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
|
MX339797B
(es)
|
2005-10-18 |
2016-06-10 |
Allergan Inc |
Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior.
|
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
EA200901041A1
(ru)
|
2007-02-06 |
2010-02-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
|
EP1974739A1
(en)
*
|
2007-03-21 |
2008-10-01 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Methods and compounds for modulating inflammatory processes
|
|
WO2009020590A1
(en)
|
2007-08-07 |
2009-02-12 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
|
BRPI0705396B1
(pt)
*
|
2007-12-12 |
2021-10-05 |
Universidade Estadual De Campinas - Unicamp |
Compostos derivados ftalimídicos
|
|
JP5336516B2
(ja)
|
2008-02-07 |
2013-11-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
|
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
BRPI0901298A2
(pt)
*
|
2009-04-06 |
2011-01-04 |
Ems Sa |
derivados ftalimìdicos de compostos antiinflamatórios não-esteróide e/ou moduladores de tnf-(alfa), processo de sua obtenção, composições farmacêuticas contendo os mesmos e seus usos no tratamento de doenças inflamatórias
|
|
US20120295979A1
(en)
*
|
2011-05-03 |
2012-11-22 |
Florida Atlantic University |
Use of sulindac for protecting retinal pigment epithelial cells against oxidative stress
|
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
|
WO2014160702A1
(en)
|
2013-03-25 |
2014-10-02 |
Chs Pharma, Inc. |
Retinopathy treatment
|
|
US8906951B1
(en)
|
2013-06-24 |
2014-12-09 |
Tigercat Pharma, Inc. |
Use of NK-1 receptor antagonists in pruritus
|
|
US9198898B2
(en)
|
2013-06-24 |
2015-12-01 |
Tigercat Pharma, Inc. |
Use of NK-1 receptor antagonists in pruritus
|
|
AU2015210999A1
(en)
|
2014-01-29 |
2016-07-21 |
Otsuka Pharmaceutical Co., Ltd. |
Device-based risk management of a therapeutic
|
|
MA40687A
(fr)
*
|
2014-04-10 |
2017-03-28 |
Ifom Fondazione St Firc Di Oncologia Molecolare |
Méthodes et compositions de traitement de malformation vasculaire
|
|
SMT202300081T1
(it)
|
2014-08-22 |
2023-05-12 |
Celgene Corp |
Metodi di trattamento di mieloma multiplo con composti immunomodulatori in combinazione con anticorpi
|
|
WO2016210262A1
(en)
|
2015-06-26 |
2016-12-29 |
Celgene Corporation |
Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
|
WO2017081676A1
(en)
*
|
2015-11-09 |
2017-05-18 |
Pharmatwob |
Pharmaceutical compositions and methods for treatment of cancer
|
|
US10513515B2
(en)
|
2017-08-25 |
2019-12-24 |
Biotheryx, Inc. |
Ether compounds and uses thereof
|
|
CN118557697A
(zh)
|
2017-09-14 |
2024-08-30 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于癌症的组合治疗
|
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
|
CA3106239A1
(en)
|
2018-07-27 |
2020-01-30 |
Biotheryx, Inc. |
Bifunctional compounds as cdk modulators
|
|
AU2019381688A1
(en)
|
2018-11-13 |
2021-06-03 |
Biotheryx, Inc. |
Substituted isoindolinones
|
|
KR102143531B1
(ko)
*
|
2018-12-20 |
2020-08-12 |
영남대학교 산학협력단 |
탈리도마이드를 유효성분으로 함유하는 가축 육질 개선용 조성물
|
|
EP4143329A4
(en)
|
2020-04-28 |
2024-10-16 |
Anwita Biosciences, Inc. |
Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
|